Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.

Gaia, Tabacco,; Yu-Kwang Donovan, Tay,; Natalie E, Cusano,; John, Williams,; Beatriz, Omeragic,; Rukhana, Majeed,; Maximo Gomez, Almonte,; Mishaela R, Rubin,; John P, Bilezikian,

doi:10.1210/jc.2018-02430

Public

Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.

Published in The Journal of clinical endocrinology and metabolism • Jul 1, 2019

Authors:

Tabacco, Gaia

Tay, Yu-Kwang Donovan

Cusano, Natalie E

Abstract

CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPT...

Subject

Adult

Aged

Calcitriol

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!